Interim Report Q1 for the cell therapy company

NextCell Pharma AB

September 2022 – November 2022

cellaviva

Cellaviva™ NextCell's stem cell bank, which offers family saving of stem cells for possible future medical needs - the largest in Scandinavia.

nextcell pharma

ProTrans™ NextCell's proprietary cell product for the treatment of autoimmune and and other inflammatory diseases. Significant effect shown in diabetes.

NextCell Pharma AB (publ.) | 556965-8361 | nextcellpharma.com | cellaviva.se

Content

01.

Interim Report Q1

"NextCell", “NXTCL” or "Company" refers to NextCell Pharma AB, organization number 556965- 8361. The amount in brackets refers to the corresponding period in the previous year. Note that the Company's fiscal year is September 1-August 31. This English version is a translation of the Swedish version. The Swedish version is at all times to be seen as the leading document.

First quarter (2022-09-01 until 2022-11-30)

- Operating income amounted to 3 012 (1 347) TSEK, of which Cellaviva counted for 2 137 (1 346)
- Operating result amounted to –8 918 (-6 472) TSEK.
- Earnings per share* amounted to -0,26 (-0,19) SEK.
- Cash and bank amounted to 88 259 (133 464) TSEK.
- Solidity** amounted to 92,0 (94,1) %.

Twelve months (2021-09-01 till 2022-08-31)

- Operating income amounted to 6 229 (4 455) TSEK.
- Operating result amounted to -34 554 (-24 557) TSEK.
- Earnings per share* amounted to -1,01 (-0,81) SEK.
- The Board of Directors proposes that no dividend is to be paid for the financial year.

**Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the first quarter 2021/2022: 34 379 523 (34 379 523) shares. Number of shares in NextCell as of November 30, 2022: 34 379 523 (34 379 523) shares.*
***Solidity: Own capital’s share of the sheet total.*

Significant events in the first quarter

- NextCell announced in early September that the company's CEO Mathias Svahn gives a status update at Nordic Life Science days in Malmö, which is the Nordic region's largest partnering event in Life Science.

- In early October, the company published a debate article on particle in cell and gene therapy products with the International Society for Cell and Gene Therapy's Process Development, Manufacturing and Analytics Committee in the journal Cytotherapy.

- NextCell announced in mid-October that patients with type-1 diabetes that has undergone two treatments with a high dose of ProTrans cell therapy has maintained significantly higher endogenous insulin production than patients treated with low and medium dose.

- At the end of October, NextCell's CEO, Mathias Svahn, presented an update on the Company's achieved and ongoing clinical operations with the drug candidate ProTrans, which has been developed for type-1 diabetes, and other autoimmune and inflammatory diseases.

Significant events after the reporting period

- NextCell announced in mid-December that the first two adolescents in the older age cohort (12-21 years) had undergone treatment in phase II part of the pediatric diabetes study.

- The company announced in mid-January that it had received positive comments and recommendations on the proposal for pediatric plan (PIP) previously submitted to the Paediatric Unit of the European Medicines Agency (PDCO).

- NextCell announced at the end of January that it is expanding the ProTrans study in COVID-19 to the treatment of severe pneumonia caused by influenza, RS and HMP viruses.

02.

NextCell Pharma

- next generation cell therapy

NextCell's drug candidate ProTrans represents a platform technology for developing and manufacturing cell therapies to treat autoimmune diseases and inflammatory conditions. The company has come the furthest with ProTrans for the treatment of type-1 diabetes where both safety and efficacy in the preservation of patients' ability to produce their own insulin have been demonstrated in clinical drug trials.

Company history

2014
The company was founded by scientists at Karolinska Institutet including Dr Mathias Svahn, CEO, and Professor Edvard Smith, CMO.

2015
Launch of family savings of stem cells from umbilical cord blod and umbilical cord tissue.

2016
First batch of the pharmaceutical candidate ProTrans produced according to GMP.

2017
The first clinical trial with ProTrans is approved, ProTrans-1.

2018
ProTrans-1 demonstrates safety in all three evaluated doses.

2019
All patients treated ProTrans-1 and ProTrans-Repeat demonstrates efficacy in an interim analysis of results from ProTrans-1.

2020
Positive data with statistical significance is published for ProTrans-2.

2021
Clinical trials for the treatment of COVID-19 with ProTrans are started.

2022
First child with type-1 diabetes treated with ProTrans.

Note: To simplify for the reader, the short name of the study titles has been changed. Formally, ProTrans-1 and ProTrans-2 are a single phase I/II study with EudraCT No: 2017-002766-50. ProTrans-Repeat can be seen as a continuation study of ProTrans-1 where patients in the dose escalation part have undergone an additional treatment with ProTrans, EudraCT No: 2018-004158-11.

03.

CEO comments

Development of ProTrans rushes forward, expansion of study for the treatment of viral infections, ongoing pediatric study with completed safety part and a clear Regulatory plan towards market approval.

In this first quarter of NextCell's broken financial year, we have presented long-term data from our first studies. The results show that a treatment with ProTrans provides long-lasting safe effect to delay the course of the disease of type-1 diabetes. It is by far the most important Event. The fact that we have received our basic patent for ProTrans approved in several regions and our significant lead over any Competitors also feel reassuring.

The children's study has, after the Safety Committee approved results from the first six patients, now entered the phase-II part and some adolescents have already undergone treatment. NextCell has received positive feedback on the proposed Paediatric Investigation Plan (PIP) by the European Medicines Agency. Only small changes have been requested to ensure prescribing marketability to a younger age group and possible off-label use. EMA's proposed changes strengthen our plan and we will: these are implemented before PIP is approved.

The first medicine for type-1 diabetes aimed at affecting the underlying disease, was approved in the United States in November. Tzield is a antibody that binds to certain immune system cells (T cells) and is given to patients who havein a precursor to diabetes

The fact that there is now a drug on the market is very good for NextCell. Tzield sets a new standard for diabetes treatment. Drug aimed at affecting the underlying disease, was approved in the United States in November. Tzield is a antibody that binds to certain immune system cells (T cells) and is given to patients who havein a precursor to diabetes. The fact that there is now a drug on the market is very good for NextCell. Tzield sets a new standard for diabetes treatment. Drug given intravenously for 14 consecutive days and also requires premedication to reduce side effects. Total cost of a treatment with Tzield has been estimated at more than $200,000. ProTrans can be a cheaper alternative, causes no known serious side effects and providescomparable effect. I think the results point to an infusion of ProTrans is more effective than 14 injections of Tzield when compared to previous studies.

The work to establish our GMP facility continues. The first experimental cultivations in the cleanrooms have been carried out and we are working purposefully to soon be able to initiate full-scale validation cultivations.

Sales in Cellaviva are steadily increasing and EuroStars grants during the The quarter gave an extra boost to the revenue side, while the establishment of As a result of in-house production, costs have also increased as planned.

NextCell has a stable cash position and we continue to build value in the company.

Thank you for your support! We look forward to an eventful 2023.

Mathias Svahn, Ph.D.
CEO NextCell Pharma AB

04.

Employees

Diana Skog appreciates the independent and alternately role of phlebotomist at Cellaviva

Stem cells from umbilical cord blood are currently used to treat a large number of serious diseases. Research suggests that umbilical cord stem cells, in particular, will revolutionize the treatment of degenerative diseasesin the future. For Diana Skog, who since 2021 working as a phlebotomist at Cellaviva, feels the work of collecting stem cellsfrom newborns both developing, meaningful and rewarding.

– I am a trained assistant nurse and worked for many years in the travel industry before I applied to the Cardiac Intensive Care Unit at Danderyd Hospital when they need to increase resources in connection with with the Corona pandemic. After a period at my new workplace, I talked me with a neighbor who is a phlebotomist at Cellaviva. She told me about their work and I thought it sounded like an interesting development opportunity," says Diana Skog.

She applied for a job at Cellaviva and is now working full-time as a phlebotomist. The work is independent and involves her being part of a team of phlebotomists with overall responsibility for their customers. She informs them of the collection of stem cells in connection with: the birth takes place and is in place at the end of the birth to be able to collect stem cells from the newborn baby. Diana Forests are also responsible for the logistics of the collected stem cells and the report collection results to the new parents

Special feeling to be involved in the moment of childbirth

– I meet a lot of gratitude from our customers and have also the privilege of being involved when their children are born, which is obviously One of the greatest moments in the lives of new parents. It's a of the factors that make my work so rewarding. Of course, it also feels meaningful to contribute to as many people as possible being able to take part in the stem cell treatment of the future," says Diana Skog. – It's fun to be a part of Cellaviva and thus indirectly also be part of NextCell Pharma. Here I am part of an expansive business and my role is varied. One day I collect stem cells in a delivery room, the next day I pack boxes and print certificates to our customers, to focus on customer contacts for a third day. Interest in collecting and saving umbilical cord stem cells is steadily increasing. In recent years, I have noted a increased awareness, more and more Considers stem cell collection as a long-term investment in its children's health, says Diana Skog.

> I experience a lof of gratitude from our customers and also have the privilege of being involved when their children is born, which obviously is one of the largest The moments in the new parents' lives."

05.



ProTrans™

- a platform technology

ProTrans™ (ProTrans) is the Company's first drug candidate, based on a patented selection algorithm and designed for the treatment of type-1 diabetes. Treatment normalizes the immune system and stops the autoimmune inflammation. The efficacy of ProTrans can be beneficial in a variety of areas where there are currently no suitable treatment options.

NextCell has developed next-generation cell therapy with mesenchymal stroma cells (also called stem cells), MSC. There are currently similar drugs that are approved for the treatment of, among other things, children affected by graft against host disease (GVHD) after bone marrow transplantation and treatment of severe Crohn's disease. The potential of MSC-based cell therapy is significantly greater. ProTrans is a further development with a focus on increasing the number of indications and treatment effect.

NextCell's patent-pending selection algorithm distinguishes ProTrans from other MSC treatments. The algorithm weighs together the results of functional analyses designed based on the cells' known mechanism of action for balancing the immune system.

There are large variations between different cells when analyzed in functional analyses. By selecting cells, the variation can be reduced. ProTrans is manufactured by MSC from umbilical cord tissue containing young and viable cells that have not yet been exposed to stress, aging or environmental impact.

MSC treatments have been evaluated since the 1990s and have shown good safety without any serious side effects. Unfortunately, the effect has been varied and therefore we now have developed a robust, reproducible selection for ProTrans.

Diabetes

Type-1 diabetes is an autoimmune disease in which the body's immune system attacks and destroys the insulin-producing beta cells in the pancreas so that they can no longer produce insulin. It is a life-threatening, incurable disease and at present, the person affected will have to live with the disease for the rest of their lives.

ProTrans has been shown to slow the progression of the disease in adult patients newly diagnosed with type-1 diabetes. Although the patients treated continue to need extra insulin, a small residual insulin production may mean better blood sugar control and ultimately counteract complications and consequential diseases.

COVID-19

Infection of Sars-CoV-2 can in the worst case lead to hyperinflammation of the lungs, which is a life-threatening condition that at the beginning of the pandemic was associated with high mortality.

ProTrans' potential to reverse hyperinflammation in the lungs is now being evaluated in two clinical trials. The aim is to treat patients before get so sick that they need to be put on a ventilator, which can be life-saving and reduce rehabilitation time.

COVID-19 is an example of virus-mediated sepsis hitting the lungs. There are a variety of other viruses and causes of hyperinflammation in the lungs, so although the pandemic is hopefully soon over, the need for this type of treatment will remain.

06.

Clinical drug trials with ProTrans™

It has been over 4 years since the first patient was treated with ProTrans at Karolinska University Hospital's trial clinic. Since then, a total of 53 patients have participated in clinical trials with ProTrans. Five studies are ongoing, of which three are actively recruiting and another 100 patients will be included.

ProTrans exhibits excellent safety profile in chronic autoimmune disease (type-1 diabetes) and acute hyperinflammation (severe COVID-19). The breadth shows the great advantage of cell therapy compared to small molecules and antibodies that often cause serious side effects.

ProTrans provides a statistically significant treatment effect in patients newly diagnosed with type-1 diabetes. A single infusion of ProTrans leads to elevated preservation of body-specific insulin production for at least one year. In the randomized placebo-controlled Phase 2 study ProTrans-2, the treated group lost an average of 10% of insulin production over a year because placebo lost nearly 50%.

The long-term effect is evaluated in ProTrans-OBS and ProTrans-Repeat where one infusion is also compared with two infusions. The studies follow the patiences for 5 years.

It has previously been shown that children with GvHD respond better to treatment with MSC compared to adults and it is possible that it is on the same way in type-1 diabetes. It is also in the paediatric population that the value of delaying the course of the disease is greatest. ProTrans-Young is the largest clinical trial with a total of 66 children from the age of 7.



07.

Cellaviva – from birth to life

The parent-to-be has many decisions and opportunities ahead of them, one of which concerns the stem cells that remain in the umbilical cord and placenta, after the baby is born and the umbilical cord is cut off. Stem cells are currently used as standard treatment in many different disease areas and are being researched in even more. Umbilical cord tissue and cord blood are sources of stem cells now used in transplant medicine and provide new treatment options for families around the world.

Cellaviva acts in close collaboration with healthcare, authorities and researchers in medicine. Since 2018, the company has been treating patients with donated umbilical cord stem cells for multiple diagnoses. Recently, privately paired stem cells from umbilical cord blood have also been handed over to Rigshospitalet in Denmark, on behalf of the family who chose to save them. A sibling of the child whose umbilical cord blood has been stored in cellaviva's biobank, suffers from a serious blood disease that must be treated with stem cells.

What was initially a distant mission, to contribute to the development of new therapies and the expansion of treatment options for affected patients, is now a reality. About 50 patients have been treated with stem cells from Cellaviva's biobank, both donated and privately saved stem cells. As knowledge of national and global research advances and treatments for previously incurable diseases spreads outside the medical and research community, the demand for stem cell savings as a service among private individuals increases. News from the outside world succeeds each other. As recently as 2022, news of a woman cured of HIV using umbilical cord stem cells reaches the general public.

Scandinavias largest private stem cell bank

Cancer continues to be the most common cause of death for children between the ages of 1 and 14 in Sweden, while sibling donation for the treatment of childhood leukemia is the most common use of stem cells saved for private use in biobanks such as Cellaviva.

Advances in research into regenerative medicine in relatively common diagnoses such as autism and CP injury also mean that interest in stem cell sparing is increasing. The results of more and more studies show that stem cells from umbilical cord blood can improve motor function and brain activity in children with neurological diseases and conditions. Of course, contributing and enabling life-saving disease treatments is always a strong driving force. But stem cells can also make available therapies that can significantly improve the quality of life for patients with chronic diseases and their families.

Stem cells are used today to treat a variety of serious diseases, such as congenital blood and immunodeficiency diseases, blood cancer, bone marrow diseases and hereditary metabolic diseases. By saving the newborn baby's stem cells, severe diseases can be treated and waiting times shortened in the event of a critical disease course because matching stem cells are already available.

Read more about stem cell treatments at
https://cellaviva.se/stamceller-som-nutidens-behandling-och-framtidens-potential/

The team continues to grow!

Cellaviva continues the network project of starting up a nationwide staff pool of phlebotomists, to meet the growing interest in stem cell savings from families across the country.

There are more and more parents who want to save stem cells, but staffing all maternity wards, 24 hours a day, in elongated Sweden is difficult. Cellaviva has therefore started a network project of experts in childbirth who, like us, want to help expectant parents get the birth they want.

Without burdening an already strained obstetric care, Cellaviva works towards the goal of having the opportunity to offer present staff to the parent couples who wish, regardless of geography. Medically trained staff with childbirth experience are linked to the company and trained to flexibly help customer families in their vicinity.

08.

Development in numbers during the period

CFO Patrik Fagerholm comments on financial development.

Amounts in brackets refer to the corresponding period of the previous year.

Turnover

Operating income for the first quarter of 2022/2023 amounts to SEK 3.0 (1.3) million, of which SEK 2.1 (1.3) million relates to revenues from Cellaviva's operations, which means an increase of close to 60 percent between the periods. Other income for the first quarter 2022-2023 am ounts to SEK 0.9 (0.0) million and consists of research grants. Revenues related to Cellaviva show steady growth over the past two years.

Financial development

The result for the first quarter 2021/2022 amounts to SEK -8.9 (-6.5) million and the total cost base for the period amounts to SEK -12.1 (-7.9) million which means an increase of SEK 4.2 million (53 percent). The increase is on budget and can mainly be attributed to one-off costs for sub-consultants working on the completion of the GMP facility.

Liquidity

NextCell's cash and cash equivalents as of 30 November 2022 amount-ed to SEK 88.2 (133,5) million. Total cash flow for the first quarter 2022/2023amounted to SEK -8.9 (-5.7) million. Cash flow from operat-ing activi- ties for the first quarter is SEK -8.4 (-5.8) million.

Solidity

The company's solidity ratio as of November 30, 2022 was 92.0 (94.1) %.

The stock and the largest shareholders

The company's share is listed on First North Growth Market and is traded under the ticker "NXTCL". As of 30 November 2022, the number of shares amounted to 34,379,523 (34,379,523) and the share capital to SEK 7,047,802 (7,047,802). The average number of shares during the first quarter amounted to 34,379,523 (34,379,523). All shares are of the same type and denominated in Swedish kronor (SEK).

As of December 31, 2022, the number of shareholders amounted to approximately 2,100 (2,600). The ten largest shareholders held shares corresponding to 46.2% of the total number.

The list below shows the ten largest shareholders in NextCell as of 31/12/2022

NAME	NO. OF SHARES	VOTES AND CAPITAL (%)
Diamyd Medical AB	4 283 861	12.5
Försäkringsbolaget Avanza Pension	3 547 460	10.3
Anders Essen-Möller*	2 526 909	7.4
Ålandsbanken I ägares ställe	1 223 243	3.6
Christer Jansson	1 003 667	2.9
Pabros AB	847 452	2.5
Nordnet Pensionsförsäkring AB	699 941	2.0
Konstruktions och Försäljningsaktiebolaget KFAB	650 000	1.9
Nordea Livförsäkring i Sverige AB	590 619	1.7
Filip Wirefors	497 000	1.4
In total	**15 870 152**	**46.2**

** In addition to Chairman of the Board, Anders Essen-Möller's directly registered holdings, this item includes holdings of 4.08 percent managed in Avanza Pension.*

Accounting principles for the preparation of the Interim Q1 Report

The Interim Q1 has been prepared in accordance with the Annual Accounts Act and BFNAR 2012:1 Annual Report and Consolidated Accounts ("K3") and in accordance with BFNAR 2007:1 ("Voluntary Interim Reporting"). For further information on accounting policies, we refer to NextCell's Annual Report for 2021/2022.

Auditor's review

The yInterim Q1 Report has not been reviewed by the Company's auditor.

Certified adviser

Companies affiliated with Nasdaq First North Growth Market require a Certified Adviser. NextCell has appointed FNCA Sweden AB as Certified Adviser, 08-528 00 399, info@fnca.se.

Financial calendar

The company prepares and publishes a financial report at the end of each quarter. Upcoming reports and events are planned as follows:

Interim Report 2	2023-04-27
Interim Report 3	2023-07-27
Year-End Report	2023-10-26
Annual Report	2023-11-09
Annual Shareholders Meeting	2023-11-30

Publication of the Interim Q1 Report

Huddinge, 26 January 2022
NextCell Pharma AB

Board of Directors and CEO

Anders Essen-Möller
CHAIRMAN OF THE BOARD

Camilla Sandberg
BOARD MEMBER

Hans-Peter Ekre
BOARD MEMBER

Edvard Smith
BOARD MEMBER

Mathias Svahn
CHIEF EXECUTIVE OFFICER

09.

Income statement

(SEK)	2022-09-01 2022-11-310	2021-09-01 2021-11-30	2021-09-01 2022-08-31
	3 months	3 months	12 months
Operating Income			
Net Income	2 136 967	1 346 226	5 588 797
Other operaing Income	875 401	1 116	640 328
Total Operating Income	**3 012 368**	**1 347 342**	**6 229 124**
Operating Expense			
Material and goods	-2 249 912	-1 102 768	–8 722 653
Other external costs	-6 371 584	-4 076 240	–19 126 853
Personnel costs	- 3 347 856	-2 619 189	–12 725 542
Depreciation	-111 968	-122 178	–457 342
Other operating expenses	-8 585	-43	–220 618
Total operating expense	**-12 089 905**	**-7 920 332**	**–41 253 008**
Operating result	**-9 077 537**	**-6 572 990**	**–35 023 884**
Financial income and expenses			
Interest received	162 005	104 071	483 097
Interest expenses and similar expenses	-2 685	-3 356	–13 528
Total financial items	**159 320**	**100 715**	**469 569**
Result before tax	**-8 918 217**	**-6 472 275**	**–34 554 315**
Taxes			
Tax expense for the period	0	0	0
Net result for the period	**-8 918 217**	**-6 472 275**	**–34 554 315**

10.

Balance sheet

(SEK)	2022-11-30	2021-11-30	2022-08-31
ASSETS			
Non-current assets			
Tangible non-current assets			
Property, plant and equipment	1 145 573	1 624 913	1 228 986
Inventories, tools and equipment	1 152 141	1 156 351	1 111 670
Fixed assets in progress	8 134 466	0	7 560 234
	10 432 180	**2 781 264**	**9 900 890**
Financial assets			
Shares and interest in other companies	6 871 525	5 114 736	6 871 525
Other long term receivables	1 128 193	1 128 192	1 128 193
	7 999 718	**6 242 928**	**7 999 718**
Total non-current assets	**18 431 897**	**9 024 192**	**17 900 607**
Current assets			
Stock and inventorie.			
Raw material	766 969	0	766 969
Current receivables			
Trade receivables	1 282 441	3 514 147	1 777 119
Other receivables	1 043 674	901 509	931 666
Prepaid expenses and accrued income	6 154 121	5 649 782	6 161 693
	8 480 237	**10 065 438**	**8 870 478**
Liquid assets	**88 258 952**	**133 464 196**	**97 117 211**
Total current assets	**97 506 158**	**143 529 634**	**106 754 658**
TOTAL ASSETS	**115 938 055**	**152 553 826**	**124 655 265**

Balance sheet cnd.

(SEK)	2022-08-31	2021-11-30	2022-08-31
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share capital	7 047 802	7 047 802	7 047 802
Non-restricted equity			
Profit or loss brought forward	–87 938 575	–53 384 260	–53 384 260
Shareholders surplus	196 429 502	196 429 502	196 429 502
Result for the period	–8 918 217	–6 472 276	–34 554 315
	99 572 710	**136 572 966**	**108 490 927**
Total equity	**106 620 512**	**143 620 768**	**115 538 729**
Liabilities			
Long-term liabilities			
Other long-term liabilities	2 358 827	1 688 088	2 184 602
Current liabilities			
Trade payables	2 083 641	4 184 732	1 924 406
Other liabilities	737 005	1 000 798	846 984
Prepaid income and accrued expenses	4 138 069	2 059 440	4 160 544
	6 958 716	**7 244 970**	**6 931 934**
Total liabilities	**9 317 543**	**8 933 058**	**9 116 536**
TOTAL EQUITY AND LIABILITIES	**115 938 055**	**152 553 826**	**124 655 265**

11.

Cash flow statement

(SEK)	2022-09-01 2022-11-30	2021-09-01 2021-11-30	2021-09-01 2022-08-31
	3 months	3 months	12 months
Operating activities			
Operating profit/loss	-9 077 537	-6 572 991	-35 023 884
Non-cash flow items			
Depreciation	111 968	122 178	457 342
Revenue from disposal of assets			135 580
Interest received	162 005	104 071	483 096
Interest paid	-2 685	-3 356	-13 528
Cash flow from operating activities before changes in working capital	**-8 806 249**	**-6 350 098**	**-33 961 393**
Changes in working capital			
Increase/decrease in receivables	390 241	-2 753 258	-1 558 298
Increase/decrease in payables	-132 454	384 703	2 190 476
Increase/decrease in stock and inventories	0	0	-766 969
Increase/decrease in short term payables	159 235	2 923 273	784 464
Total of working capital	**417 023**	**554 717**	**649 673**
Net cash flow from operating activities	**-8 389 226**	**-5 795 381**	**-33 311 720**
Investing activities			
Investments in material and immaterial assets	-643 258	0	-7 590 369
Investments in financial assets	0	0	-1 756 790
Net cash flow from investment activities	**-643 258**	**0**	**-9 347 159**
Financing activities			
Long term liabilities	174 226	91 665	608 169
Net cash flow from financing activities	**174 226**	**91 665**	**608 169**
Cash flow for the period			
Cash and cash equivalents at beginning of period	97 117 211	139 167 921	139 167 921
Change in cash and cash equivalents	-8 858 259	-5 703 716	-42 050 710
CASH AND CASH EQUIVALENTS AT END OF PERIOD	**88 258 952**	**133 464 205**	**97 117 211**

12.

Statement of changes in equity

	SHARE CAPITAL	BALANCED RESULT	SHARE PREMIUMS	NET RESULT OF THE PERIOD	TOTAL EQUITY
Opening balance 2021-09-01	**7 047 802**	**-28 827 505**	**196 429 502**	**-24 556 755**	**150 093 044**
Disposition from AGM		-24 556 755		24 556 755	0
New Issue					0
Cost related to the new issue					0
Result				-34 554 315	-34 554 315
Closing balance 2022-08-31	**7 047 802**	**-53 384 260**	**196 429 502**	**-34 554 315**	**115 538 729**

	SHARE CAPITAL	BALANCED RESULT	SHARE PREMIUMS	NET RESULT OF THE PERIOD	TOTAL EQUITY
Opening balance 2022-09-01	**7 047 802**	**–53 384 260**	**196 429 502**	**–34 554 315**	**115 538 729**
Disposition from AGM		–34 554 315		34 554 315	0
New Issue	0		0		0
Cost related to the new issue			0		0
Result				–8 918 217	–8 918 217
Closing balance 2022-11-30	**7 047 802**	**–87 938 575**	**196 429 502**	**–8 918 217**	**106 620 512**

Company information

Company name: NextCell Pharma AB (Publ.)
Organization number: 556965-8361
Legal corporate form: Publikt aktiebolag
Place: Huddinge

Trading place: Nasdaq First North Growth Market
Address: Hälsovägen 7, 141 57 Huddinge
Telephone: +46 8 735 55 95
Web page: www.nextcellpharma.com | www.cellaviva.se